Kamao Tomoyuki, Zheng Xiaodong, Shiraishi Atsushi
Department of Ophthalmology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan.
BMC Ophthalmol. 2021 Feb 25;21(1):103. doi: 10.1186/s12886-020-01678-5.
The dacryoendoscope is the only instrument that can observe the luminal side of the lacrimal passage with minimal invasiveness. It was developed to treat lacrimal passage obstructions by inserting a bicanalicular nasal stent with sheath-guided bicanalicular intubation (SG-BCI). The purpose of this study was to determine the outcomes of SG-BCI to treat lacrimal passage obstructions. In addition, to determine the effects of SG-BCI treatment on the quality of life.
This was a retrospective observational study of 128 patients (mean age 70.9 ± 11.0 years, range 28-93 years) diagnosed with a unilateral lacrimal passage obstruction. There were 73 patients with a nasolacrimal duct obstruction, 37 with a lacrimal canaliculus obstruction, 7 with a lacrimal punctum obstruction, and 11 with common lacrimal canaliculus and nasolacrimal duct obstructions. They were all treated with SG-BCI. The postoperative subjective outcomes were assessed by the answers to the Glasgow Benefit Inventory (GBI) questionnaire and to an ocular specific questionnaire on 6 symptoms including tearing, ocular discharges, swelling, pain, irritation, and blurred vision. The objective assessments were the surgical success rates and the patency at 6 months after the bicanalicular nasal stent was removed. The patients were divided into those with a pre-saccal obstruction, Group 1, and with a post-saccal obstruction, Group 2. The subjective and objective outcomes were compared between the two groups.
One hundred twenty-four sides (96.9%) had a successful probing and intubation of the lacrimal passage obstruction by SG-BCI. Of the 124 sides, 110 sides (88.7%) retained the patency after the stent was removed for at least 6 months. The GBI total, general subscale, social support, and physical health scores were + 37.1 ± 29.0, + 41.5 ± 30.0, + 28.0 ± 39.4, and + 24.1 ± 37.7, respectively, postoperatively. All of the 6 ocular specific symptom scores improved significantly postoperatively. The postoperative score of tearing improved in Group 1 (P < 0.0001), while the postoperative scores of all symptoms improved significantly in Group 2.
The relatively high surgical success rates and positive GBI scores, and improved ocular symptom scores indicate that SG-BCI is a good minimally invasive method to treat lacrimal passage obstructions.
泪道内窥镜是唯一能够以微创方式观察泪道管腔侧的仪器。它通过插入带鞘引导双泪小管插管(SG-BCI)的双泪小管鼻支架来治疗泪道阻塞。本研究的目的是确定SG-BCI治疗泪道阻塞的效果。此外,确定SG-BCI治疗对生活质量的影响。
这是一项对128例诊断为单侧泪道阻塞患者(平均年龄70.9±11.0岁,范围28 - 93岁)的回顾性观察研究。其中73例为鼻泪管阻塞,37例为泪小管阻塞,7例为泪小点阻塞,11例为泪总管和鼻泪管联合阻塞。他们均接受了SG-BCI治疗。术后主观结果通过对格拉斯哥获益量表(GBI)问卷以及一份关于包括流泪、眼部分泌物、肿胀、疼痛、刺激和视力模糊6种症状的眼部特定问卷的回答进行评估。客观评估为双泪小管鼻支架取出后6个月时的手术成功率和通畅率。患者被分为泪囊前阻塞组(第1组)和泪囊后阻塞组(第2组)。比较两组的主观和客观结果。
124侧(96.9%)通过SG-BCI成功探测并插管治疗泪道阻塞。在这124侧中,110侧(88.7%)在支架取出后至少6个月保持通畅。术后GBI总分、一般分量表、社会支持和身体健康得分分别为 +37.1±29.0、+41.5±30.0、+28.0±39.4和 +24.1±37.7。所有6种眼部特定症状得分术后均显著改善。第1组术后流泪得分改善(P < 0.0001),而第2组所有症状术后得分均显著改善。
相对较高的手术成功率、积极的GBI得分以及改善的眼部症状得分表明,SG-BCI是治疗泪道阻塞的一种良好的微创方法。